Rhythm Pharmaceuticals (RYTM) EBIT (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly EBIT of -$52.4 million for Q1 2026, down 11.4% year-over-year from -$59.1 million in Q1 2025, and down 11.26% quarter-over-quarter from -$47.1 million in Q4 2025.
Powered by 
Analysis
Rhythm Pharmaceuticals (RYTM) EBIT (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported EBIT for 11 consecutive years, with -$52.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 11.4% year-over-year to -$52.4 million; the TTM figure through Mar 2026 stood at -$197.4 million (down 14.34% YoY), while the FY2025 annual figure was -$192.0 million, up 27.68% from the prior year.
- EBIT fell to -$52.4 million in Q1 2026 per RYTM's latest filing, from -$47.1 million in the prior quarter.
- Across five years, EBIT topped out at -$39.3 million in Q3 2022 and bottomed at -$139.9 million in Q1 2024.
- Historically, EBIT has averaged -$51.4 million across 5 years, with a median of -$45.3 million in 2025.
- Annual changes were most pronounced in 2024 — EBIT tumbled 166.29% — and 2025, when it surged 66.4%.
- Rhythm Pharmaceuticals' EBIT stood at -$42.1 million in 2022, then increased by 1.99% to -$41.3 million in 2023, then rose by 0.02% to -$41.3 million in 2024, then dropped by 14.08% to -$47.1 million in 2025, then dropped by 11.26% to -$52.4 million in 2026.
- Business Quant data shows RYTM's EBIT at -$52.4 million in Q1 2026, -$47.1 million in Q4 2025, and -$52.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Rhythm Pharmaceuticals | 7.06 Bn | 6.73 Bn | 62.32 Mn | -48.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -48.55 Mn |
| Mar 31, 2026 | -52.36 Mn |
| Dec 31, 2025 | -47.06 Mn |
| Sep 30, 2025 | -52.65 Mn |
| Jun 30, 2025 | -45.30 Mn |
| Mar 31, 2025 | -47.00 Mn |
| Dec 31, 2024 | -41.26 Mn |
| Sep 30, 2024 | -43.89 Mn |
| Jun 30, 2024 | -40.48 Mn |
| Mar 31, 2024 | -139.89 Mn |
| Dec 31, 2023 | -41.27 Mn |
| Sep 30, 2023 | -43.95 Mn |
| Jun 30, 2023 | -46.60 Mn |
| Mar 31, 2023 | -52.53 Mn |
| Dec 31, 2022 | -42.10 Mn |
| Sep 30, 2022 | -39.27 Mn |
| Jun 30, 2022 | -45.10 Mn |
| Mar 31, 2022 | -52.69 Mn |
| Dec 31, 2021 | -50.99 Mn |
| Sep 30, 2021 | -44.24 Mn |